Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lantheus

55.66
-0.5000-0.89%
Volume:918.29K
Turnover:51.29M
Market Cap:3.78B
PE:14.75
High:56.88
Open:56.41
Low:55.47
Close:56.16
52wk High:118.21
52wk Low:47.25
Shares:67.99M
Float Shares:59.94M
Volume Ratio:0.34
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.77
EPS(LYR):4.52
ROE:24.71%
ROA:13.34%
PB:3.24
PE(LYR):12.33

Loading ...

Company Profile

Company Name:
Lantheus
Exchange:
NASDAQ
Establishment Date:
1956
Employees:
808
Office Location:
201 Burlington Road,South Building,Bedford,Massachusetts,United States
Zip Code:
01730
Fax:
978 671 8860
Introduction:
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Directors

Name
Position
Brian Markison
Director and Chief Executive Officer
Gary J. Pruden
Independent Director
Gerard Ber
Independent Director
Heinz Mausli
Independent Director
James H. Thrall
Independent Director
Julie H. McHugh
Lead Independent Director
Julie M. Eastland
Independent Director
Mary Anne Heino
Chairperson of the Board
Minnie V. Baylor Henry
Independent Director
Phuong Khanh Morrow
Independent Director
Samuel Leno
Independent Director

Shareholders

Name
Position
Brian Markison
Director and Chief Executive Officer
Robert J. Marshall, Jr.
Chief Financial Officer and Treasurer
Daniel M. Niedzwiecki
Chief Administrative Officer, General Counsel and Corporate Secretary
Jamie Spaeth
Chief People Officer
Jean Claude Provost
Chief Science Officer
Kimberly Brown
Chief Accounting Officer
Paul Blanchfield
President